AbstractObjective: To analyze and study the results and clinical safety of a treatment regimen of conventional drugs combined with levosimendan in hospitalized patients with acute decompensated heart failure (ADHF) over a short course of treatment. Methods: A total of 160 patients with ADHF admitted to the Second Affiliated Hospital of Anhui Medical University from July 2018 to July 2022 were selected and divided into control group with conventional medication and experimental group with levosimendan combined with conventional medication, 80 cases in each group. Left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD) , N-terminal pro-B-type natriuretic peptide(NT-proBNP) , cardiac troponin I (cTnI), and cardiac functional grading were collected at admission and one week after treatment. At the same time, the therapeutic effect was analyzed and evaluated. Results: After treatment, LVEF levels of all subjects increased( both P<0.05 ). There were a significant decrease in the level of LVEDD、NT-proBNP、cTnI for both groups compared with those before treatment( both P<0.05 ). After the treatment of levosimendan, the magnitude of changes in LVEF, LVEDD, NT-proBNP and cTnI of the patients in the experimental group was better than that in the control group, and the difference between the two groups was significant (all P<0.05). Conclusion: Levosimendan in combination with conventional drugs improves myocardial function and slows down clinical symptoms in hospitalized patients with acute decompensated heart failure, and is safe and effective.
HU Leyi,ZHOU Shu,CHENG Jinglin, et al. Short-Term Efficacy and Safety of Levosimendan in the Treatment of Patients with Acute Decompensated Heart Failure[J]. HeBei Med, 2023, 29(10): 1725-1730.
[1] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789. [2] Yandraoalli S,Tariq S,Aronow WS.Advances in chemical pharmacotherapy for managing acute decompensated heart failure[J].Expert Opin Pharmacother,2017,18(5):1-5. [3] Packer M,Colucci W,Fisher L,et al.Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure[J].JACC Heart Fail,2013,1(2):103-111. [4] 贾志,郭牧,张丽媛,等.左西孟旦与米力农治疗心力衰竭的疗效比较[J].中华急诊医学杂志,2014,23(7):740-745. [5] Fukushima A,Kinugawa S.Renin-Angiotensin-Aldosterone system and natriuretic peptides as possible targets of waon therapy in heart failure[J].Circ,2017,81(5):635-636. [6] McDonagh TA,Metra M,Adamo M,et al.2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart,2021,42(36):3599-3726. [7] Bavendiek U,Berliner D,Davila LA,et al.Rationale and design of the DIGIT-HF trial (digitoxin to Improve outcomes in patients with advanced chronic heart failure):a randomized,double-blind,placebo-controlled study[J].Eur Heart Fail,2019,21(5):676-684. [8] Papp Z,Agostoni P,Alvarez J,et al.Levosimendan efficacy and safety:20 years of SIMDAX in clinical use[J].Cardiovasc Pharmacol,2020,76(1):4-22. [9] Comin CJ,Manito N,Sergovia CJ,et al.Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure:the LION-HEART multicentre randomised trial[J].Eur Heart Fail,2018,20(7):1128-1136. [10] Polzl G,Allipour BS,Comin CJ,et al.Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period[J].ESC Heart Fail,2019,6(1):174-181. [11] Tycinska A,Gierlotka M,Bartus S,et al.Repetitive use of LEvosimendan in ambulatory heart failure patients (LEIA-HF) - The rationale and study design[J].Adv Med Sci,2022,67(1):18-22. [12] 陈运龙,黄岚,刘小燕,等.左西孟旦治疗扩张型心肌病急性失代偿心力衰竭住院患者的短期疗效及安全性观察[J].中华心力衰竭和心肌病杂志,2020,4(4):256-260. [13] 付文科,孙玉发,郝卫军,等.左西孟旦治疗老年缺血性心肌病所致急性失代偿性心力衰竭的疗效和安全性分析[J].中华老年性脑血管杂志,2017,19(2):153-155. [14] 彭艳玲,王冉冉,黄洁,等.左西孟旦治疗慢性心力衰竭的疗效分析[J].中国急救复苏与灾害医学杂志,2018,13(6):533-535. [15] Martin J,Ana AP,Antonio LP,et al.Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients:the LAICA study[J].ESC Heart Failure,2021,8(6):4820-4831.
2023, Vol. 29 
